Dr Raminderpal Singh

Dr Raminderpal Singh

AI Solution Architect & Fractional CTO; Life Sciences

Global Head of AI/GenAI Practice · 20/15 Visioneers
Founder · HitchhikersAI

I'm an AI solution architect and entrepreneur enabling Scientific R&D organisations to move from AI‑curious to AI‑led — starting with life sciences, where I've spent the last 20 years building depth in the industry's priorities, risks, and resistance to change. I work through practical software, open‑source in‑silico workflows, and the organisational change needed to make it stick.

Engineering discipline meets AI momentum

I'm an AI Solution Architect with a deep-rooted foundation in systems engineering — trained to understand how complex pieces fit together, where the friction is, what the boundaries between components should be, and what it takes to make something work reliably at scale. That instinct shapes everything I build.

What excites me about this moment is the raw momentum that AI brings. The speed at which ideas can become working software has fundamentally changed. But momentum without structure produces fragile systems, hallucinated outputs, and untestable code.

AI has made Systems Engineering more critical, not less. When AI writes the code, the architect is still accountable. The value a human brings is no longer in the implementation — it is in requirements elicitation, defining module boundaries, and deciding what the system should actually do. Those are systems engineering decisions that no AI agent makes reliably without that discipline enforcing the structure.

That's the thread running through all my work — from teaching scientists to vibe‑code responsibly, to building test‑first workflows that keep AI agents honest, to deploying autonomous research platforms that scientists can actually trust. Two decades inside scientific R&D — understanding how experiments are designed, where data breaks down, what regulators care about, and why adoption stalls — means I build for the constraints that actually exist, not the ones that look good in a pitch deck.

Scientific R&D has an AI adoption problem — and it takes more than technology to fix it

Most scientific R&D organisations — pharma, biotech, and the vendors that serve them — know they need AI. But knowing and doing are very different things. Life sciences is where I focus first: the regulatory burden is heavy, the data is messy, the stakes are high, and the industry's track record of adopting new technology is poor.

The gap isn't one capability. It's a jigsaw of interconnected pieces: how teams write and ship software, how computational scientists run in‑silico experiments, how LLM agents make effective autonomous decisions in analytic and lab workflows, how lab data flows through automated workflows, how leadership structures adapt, and whether the culture genuinely supports change or merely talks about it.

Shipping AI‑generated code without engineering discipline accelerates technical debt — faster than ever before. I apply the iterative VP‑model — a prototyping‑at‑every‑abstraction‑layer extension of the V‑model — to enforce separation of concerns, specification‑first design, and layer‑by‑layer validation on AI coding agents. The result is auditable, maintainable software that holds up beyond the initial proof of concept. AI does the coding; engineering discipline determines whether it's worth keeping.

Solving any one piece in isolation delivers limited value. The opportunity is in solving them together.

That's why John Conway (Founder & Chief Visioneer, 20/15 Visioneers) and I have partnered to address the full jigsaw — combining AI engineering, LLM agents, and in‑silico software with organisational change, culture transformation, and FAIR data strategy. Between us, we cover the technical foundation and the human infrastructure that scientific R&D organisations need to adopt AI for real.

Accelerating the adoption of AI in Scientific R&D AI-Powered Software Development Vibe coding · Production hardening AI-generated codebase quality ↳ Raminderpal LLM Agents for Autonomous Decision Analytic & lab workflow agents Reliable reasoning · Tool use ↳ Raminderpal Open-Source In-Silico Workflows Computational chemistry Accelerated discovery pipelines ↳ Raminderpal Organisational Change & Culture Leadership alignment · Adoption Overcoming resistance to change ↳ John FAIR Data & Data Strategy Findable · Accessible Interoperable · Reusable ↳ John Data-Driven Lab Automation Automated workflows · ELN / LIMS Instrument integration · Metadata ↳ John

Six interconnected capabilities required for AI transformation in scientific R&D

Vibe Coding for Scientists

A guide to AI‑assisted development for scientific workflows — teaching scientists how to use AI tools like Claude and Cursor AI to build applications. Not about building LLM systems; about getting scientists productive with code, fast.

Education

Test‑First Orchestrator

AI coding agents generate working POCs in minutes — but POCs lack test coverage, error handling, type safety, and modular architecture. This is a test‑first development workflow for Claude Code that enforces the discipline AI agents bypass when left unconstrained.

Dev tooling
SC

ScienceClaw

An autonomous research platform for life sciences. It scans news, conducts deep research across your portfolio, finds cross‑domain connections, analyses datasets, and answers ad‑hoc questions — all through email, with no software to install.

Platform
20/15 Visioneers

AI Lab Transition

Most AI transitions in life sciences fail — not because the technology isn’t ready, but because the strategy, the organizational change, and the data foundations are treated as afterthoughts. This framework exists because the industry deserves an honest, experience‑led approach.

20/15 Visioneers
"Raminderpal, you really have a gift for this kind of teaching, and I think your time was well spent with the Broad crowd – they're quite likely to adopt the tools, teach their future labs, and spread the word!"
"This was an exceptionally useful introduction to vibe coding. Your portal is the missing manual that can get people going in one weekend!"
Dr Anne Carpenter
Senior Director, Broad Institute at Harvard & MIT
Scientific and Technical Advisory Board Member, Recursion Pharmaceuticals

HitchhikersAI

300+
community members

A non‑profit grass‑roots community accelerating the adoption of AI/ML and data in scientific R&D — starting with drug discovery & development. Members include bench scientists, data scientists, mathematicians, business owners, executives, and academics — all focused on fixing the disconnect between AI/ML/GenAI and its practical application in the lab.

AI in Drug Discovery

Regular column in Drug Target Review exploring the real‑world application of AI, ML, and generative AI in drug discovery — cutting through the hype to examine what actually works, what doesn't, and what the industry needs to do differently.

LLM in Life Sciences News Tracker

A curated tracker covering AI scientists, autonomous discovery systems, and infrastructure across pharma and biotech — from funding rounds and platform launches to partnerships and regulatory developments. Searchable and filterable by category. Updated weekly.

I’ve spent 20 years moving between technical, commercial, and leadership roles across life sciences, semiconductors, and data infrastructure. That range matters — because the AI adoption challenge in scientific R&D isn’t purely technical. It sits at the intersection of engineering discipline, domain expertise, and the ability to navigate enterprise-scale organisations.

incubate.bio

Founder & CEO · 3 years

Founded and led a company building computational platforms for drug discovery. The core product — ALaSCA — applies Pearlian causal inference to multi-omics data, moving beyond correlation-based methods to quantify how biological pathways actually drive outcomes like drug resistance. Four bioRxiv preprints: DDR resistance in cancer (2024 ↗), pathway simulation in Type 1 Diabetes (2023 ↗), causal inference in Alzheimer’s (2022 ↗), and ML target prioritisation in aging (2022 ↗).

IBM Semiconductor Group — Engineering & analytics at scale

Senior Engineering Manager → Program Director · 6 years

Program Director for Operations Research at IBM’s 300mm Fishkill fab. Led a large cross-functional team across multiple IBM organisations. Developed and deployed a predictive analytics platform with IBM Research, saving $10M+ during my leadership. Managed a department of 20 direct reports plus an extended team of 30 technical staff. Awarded 12 patents during this period. This is where I learned what it takes to make complex systems work reliably at scale — the same instinct that drives everything I build today.

Eagle Genomics

VP / Head of Microbiome Division · VP Business Development · 3 years

Led market development and product strategy across epigenetics, microbiology, multi-omics, and real-world evidence. The company’s top seller, regularly closing multi-year six-figure solution deals with blue-chip life sciences and CPG customers worldwide. I’ve sat in the commercial and product leadership seats that my clients sit in today — I understand their constraints, their internal politics, and what “adoption” actually looks like inside a large organisation.

IBM Research — Genomic medicine

Business Development & Strategy Lead · 8 years

Led the Watson genomics programme in partnership with the New York Genome Center, reporting directly to an IBM Senior Vice President. Closed multi-million dollar agreements in healthcare & life sciences, including complex IP licensing and partnership contracts. Built international experience with providers and research centres across the US, Singapore, UK, and Canada.

20/15 Visioneers

20/15 Visioneers

Global Head of AI/GenAI Practice · Current (2 years)

This is where the technical depth, domain knowledge, and enterprise experience come together. Partnered with John Conway (Founder & Chief Visioneer) to address AI adoption as the interconnected challenge it actually is — combining AI engineering, LLM agents, and in-silico software with organisational change, culture transformation, and FAIR data strategy.

Top 13 Influencers in the Semiconductor Industry

EETimes, 2003

Signal Integrity Effects in Custom IC and ASIC Designs

Book · Author

Silicon Germanium: Technology, Modeling, and Design

Book · Author

For the full picture — including patents, earlier publications, education, and additional roles — see my LinkedIn profile ↗